A Trial of PDL192 in Subjects With Advanced Solid Tumors
This is a phase 1, multicenter, open-label, dose escalation trial of PDL192 in subjects with advanced solid tumors.
Cancer
BIOLOGICAL: PDL192
Maximum tolerated dose, after four weeks of dosing
The incidence and frequency of dose-limiting toxicities; The frequency, severity, and relationship of adverse events and serious adverse events;Incidence of abnormal findings in physical examinations and clinical laboratory values, during estimated average 4 month treatment period and 90 day follow up|Pharmacokinetic profile of PDL192 including maximum serum drug concentration, area under the concentration-time curve from time zero to infinity, systemic clearance, volume of distribution, and elimination half-life, during estimated average 4 month treatment period and 90 day follow up|Incidence of PDL192-specific antidrug antibodies, during estimated average 4 month treatment period and 90 day follow up|Objective response rate (Complete Response + Partial Response) and Disease control rate (Complete Response + Partial Response + Stable Disease), during estimated average 4 month treatment period
The primary study objective is to determine the maximum tolerated dose of PDL192 in subjects with advanced solid tumors.